The Prostate, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 11, 2024
The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) plays a role in carcinogenesis is involved processes, such as proliferation, differentiation, drug resistance immunosuppression. STAT3 can be activated by phosphorylation tyrosine at position 705 (pSTAT3
Язык: Английский
Prostate Cancer and Prostatic Diseases, Год журнала: 2024, Номер unknown
Опубликована: Апрель 2, 2024
Язык: Английский
Процитировано
11
Cell Death and Disease, Год журнала: 2025, Номер 16(1)
Опубликована: Фев. 4, 2025
Язык: Английский
Процитировано
0
BMC Cancer, Год журнала: 2025, Номер 25(1)
Опубликована: Март 24, 2025
Despite advancements in the detection and treatment of prostate cancer, molecular mechanisms underlying its progression remain unclear. This study aimed to investigate role receptor OR51E2, which is commonly upregulated this disease. We investigated physiological effects OR51E2 through CRISPR-Cas9-induced monoclonal knockout. assessed vitro vivo tumorigenicity conducted transcriptomic proteomic analyses xenograft tumors derived from these knockout cells. Furthermore, we analyzed differences OR51E2-expression levels patients a TCGA cohort. OR51E2-knockout cells exhibited increased proliferation, migration, adhesion, anchorage-independent colony formation, tumor growth rates, resulting more aggressive cancer phenotype. Omics revealed several potential pathways associated with significant changes, notably an aberration STAT3 pathway linked IL-6 signaling, highlighting connection inflammatory pathways. cohort analysis that low expression had worse prognosis higher average Gleason grade than those levels. Additionally, supported putative OR51E2-related modulation pathway. regulated throughout actively influences cell physiology affecting aggressiveness. Reduced may adversely affect patient outcomes, potentially alterations impact cellular responses signaling.
Язык: Английский
Процитировано
0
Cancer Letters, Год журнала: 2024, Номер 597, С. 217070 - 217070
Опубликована: Июнь 14, 2024
Язык: Английский
Процитировано
4
Cancer Letters, Год журнала: 2025, Номер unknown, С. 217441 - 217441
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Frontiers in Oncology, Год журнала: 2025, Номер 15
Опубликована: Фев. 20, 2025
Gastric cancer (GC) remains one of the most common types cancer, ranking fifth among cancer-related deaths worldwide. Chemotherapy is an effective treatment for advanced GC. However, development chemotherapy resistance, which involves malfunction several signaling pathways and consequence numerous variables interacting, seriously affects patient leads to poor clinical outcomes. Therefore, in order treat GC, it imperative find novel medications that will increase sensitivity reverse resistance. Traditional Chinese medicine (TCM) has been extensively researched as adjuvant medication recent years. It shown have anticancer benefits be crucial enhancing reducing Given this, mechanism resistance GC summed up this work. The theoretical foundation TCM a sensitizer established by introducing primary signal possible targets implicated improving reversing active ingredients.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(5), С. 755 - 755
Опубликована: Фев. 23, 2025
Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor that strongly implicated in various cancers. In its canonical signaling pathway, Janus kinases (JAKs) phosphorylate STAT3 at the Y705 residue response to cytokines or growth factors, with pY705 serving as key marker oncogenic activity. Elevated levels correlate poor prognosis, numerous small-molecule inhibitors have been developed block this phosphorylation site. More recently, S727 (pS727) has emerged critical contributor STAT3-mediated oncogenesis, particularly due role mitochondrial translocation. Evidence suggests pS727 may even surpass driving These findings prompt an important question: Which should be prioritized for effective inhibition cancer therapy? This review compiles critically analyzes current literature on targeting and/or pS727, evaluating their therapeutic efficacy vitro, vivo, clinical trials. We assess unique effects each downstream signaling, toxicity, outcomes. Our analysis indicates both achieve greatest effectiveness. However, associated higher toxicity risks. Comprehensive evaluation underscores importance maximum benefit. The also shows co-targeting increase overall efficacy. approached lower affinity minimize enhance feasibility dual-targeting strategies.
Язык: Английский
Процитировано
0
Molecular Aspects of Medicine, Год журнала: 2025, Номер 103, С. 101359 - 101359
Опубликована: Март 4, 2025
Язык: Английский
Процитировано
0
Clinical and Experimental Medicine, Год журнала: 2025, Номер 25(1)
Опубликована: Март 25, 2025
Язык: Английский
Процитировано
0
MedComm, Год журнала: 2025, Номер 6(4)
Опубликована: Март 30, 2025
ABSTRACT Signal transducer and activator of transcription 3 (STAT3) is a critical factor involved in multiple physiological pathological processes. While STAT3 plays an essential role homeostasis, its persistent activation has been implicated the pathogenesis various diseases, particularly cancer, bone‐related autoimmune disorders, inflammatory cardiovascular neurodegenerative conditions. The interleukin‐6/Janus kinase (JAK)/STAT3 signaling axis central to activation, influencing tumor microenvironment remodeling, angiogenesis, immune evasion, therapy resistance. Despite extensive research, precise mechanisms underlying dysregulated disease progression remain incompletely understood, no United States Food Drug Administration (USFDA)‐approved direct inhibitors currently exist. This review provides comprehensive evaluation STAT3's health disease, emphasizing involvement cancer stem cell maintenance, metastasis, inflammation, drug We systematically discuss therapeutic strategies, including JAK (tofacitinib, ruxolitinib), Src Homology 2 domain (S3I‐201, STATTIC), antisense oligonucleotides (AZD9150), nanomedicine‐based delivery systems, which enhance specificity bioavailability while reducing toxicity. By integrating molecular mechanisms, pathology, emerging interventions, this fills knowledge gap STAT3‐targeted therapy. Our insights into crosstalk, epigenetic regulation, resistance offer foundation for developing next‐generation with greater clinical efficacy translational potential.
Язык: Английский
Процитировано
0